help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ohta, K.
Right arrow Articles by Onaya, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ohta, K.
Right arrow Articles by Onaya, T.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Thyroid Cancer
The Journal of Clinical Endocrinology & Metabolism Vol. 86, No. 5 2170-2177
Copyright © 2001 by The Endocrine Society

Original Studies

Ligands for Peroxisome Proliferator-Activated Receptor {gamma} Inhibit Growth and Induce Apoptosis of Human Papillary Thyroid Carcinoma Cells

Kazuyasu Ohta, Toyoshi Endo, Kazutaka Haraguchi, Jerome M. Hershman and Toshimasa Onaya

Third Department of Internal Medicine (K.O., T.E., K.H., T.O.), Yamanashi Medical University, Yamanashi 409-3898, Japan; and Endocrine Research Laboratory (J.M.H.), West Los Angeles Veterans Affairs Medical Center and University of California School of Medicine, Los Angeles, California 90073

Address all correspondence and requests for reprints to: Toshimasa Onaya, M.D., Third Department of Internal Medicine, Yamanashi Medical University, 1110 Shimo-Kato Tamaho, Yamanashi, 409-3898 Japan. E-mail: onayat{at}res.yamanashi-med.ac.jp

Ligands for peroxisome proliferator-activated receptor {gamma} (PPAR{gamma}) induce apoptosis and exert antiproliferative effects on several carcinoma cell lines. The present study investigates the expression of PPAR{gamma} and the possibility that agonists for PPAR{gamma} also inhibit the growth of human thyroid carcinoma cells. We examined this hypothesis using six cell lines, designated BHP thyroid carcinoma cells, which originated from patients with papillary thyroid carcinoma. RT-PCR analysis revealed that the thyroid carcinoma cell lines BHP2–7, 7–13, 10–3, and 18–21 express PPAR{gamma}. More PPAR{gamma} was expressed in carcinoma than in adjacent normal thyroid tissue in three of six samples of human papillary carcinoma of the thyroid.

PPAR{gamma}-positive thyroid carcinoma cells were treated with agonists of PPAR{gamma}, troglitazone, BRL 49653, and 15-deoxy-{Delta}12,14-prostaglandin J2. Troglitazone (10 µmol/L), BRL 49653 (10 µmol/L), and 15-deoxy-{Delta}12,14-prostaglandin J2 (1 µg/mL) decreased [3H]thymidine incorporation and reduced cell number, respectively, in BHP carcinoma cell lines that expressed PPAR{gamma}. Under low serum conditions, ligands for PPAR{gamma} induced condensation of the nucleus and fragmentation of chromatin into nucleosome ladders. These findings indicate that the death of thyroid carcinoma cells is a form of apoptosis.

To investigate the molecular mechanism of the apoptosis, we assessed expression of the apoptosis-regulatory genes bcl-2, bax, and c-myc. Troglitazone significantly increased the expression of c-myc messenger RNA but had no effect on the expression of bcl-2 and bax in thyroid carcinoma cells. These results suggest that, at least in part, the induction of apoptosis in human papillary thyroid carcinoma cells may be due to an increase of c-myc.

Troglitazone (500 mg/kg·day) significantly inhibited tumor growth and prevented distant metastasis of BHP18–21 tumors in nude mice in vivo.

Taken together, these results suggest that PPAR{gamma} agonist inhibit cell growth of some types of human thyroid cancer.




This article has been cited by other articles:


Home page
 Eur J EndocrinolHome page
A. Antonelli, S. M. Ferrari, P. Fallahi, P. Berti, G. Materazzi, I. Marchetti, C. Ugolini, F. Basolo, P. Miccoli, and E. Ferrannini
Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration
Eur. J. Endocrinol., September 1, 2008; 159(3): 283 - 291.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
D Bonofiglio, H Qi, S Gabriele, S Catalano, S Aquila, M Belmonte, and S Ando
Peroxisome proliferator-activated receptor {gamma} inhibits follicular and anaplastic thyroid carcinoma cells growth by upregulating p21Cip1/WAF1 gene in a Sp1-dependent manner
Endocr. Relat. Cancer, June 1, 2008; 15(2): 545 - 557.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Mariggio, B. M. Filippi, C. Iurisci, L. K. Dragani, V. De Falco, M. Santoro, and D. Corda
Cytosolic Phospholipase A2{alpha} Regulates Cell Growth in RET/PTC-Transformed Thyroid Cells
Cancer Res., December 15, 2007; 67(24): 11769 - 11778.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. Coras, A. Holsken, S. Seufert, J. Hauke, I. Y. Eyupoglu, M. Reichel, C. Trankle, F. A. Siebzehnrubl, R. Buslei, I. Blumcke, et al.
The peroxisome proliferator-activated receptor-{gamma} agonist troglitazone inhibits transforming growth factor-{beta}-mediated glioma cell migration and brain invasion
Mol. Cancer Ther., June 1, 2007; 6(6): 1745 - 1754.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
G. Riesco-Eizaguirre and P. Santisteban
A perspective view of sodium iodide symporter research and its clinical implications.
Eur. J. Endocrinol., October 1, 2006; 155(4): 495 - 512.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
T Kogai, K Taki, and G A Brent
Enhancement of sodium/iodide symporter expression in thyroid and breast cancer.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 797 - 826.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
J-R Weng, C-Y Chen, J J Pinzone, M D Ringel, and C-S Chen
Beyond peroxisome proliferator-activated receptor {gamma} signaling: the multi-facets of the antitumor effect of thiazolidinediones.
Endocr. Relat. Cancer, June 1, 2006; 13(2): 401 - 413.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
A. Y. M. Au, C. McBride, K. G. Wilhelm Jr., R. J. Koenig, B. Speller, L. Cheung, M. Messina, J. Wentworth, V. Tasevski, D. Learoyd, et al.
PAX8-Peroxisome Proliferator-Activated Receptor {gamma} (PPAR{gamma}) Disrupts Normal PAX8 or PPAR{gamma} Transcriptional Function and Stimulates Follicular Thyroid Cell Growth
Endocrinology, January 1, 2006; 147(1): 367 - 376.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
L. Lacroix, V. Lazar, S. Michiels, H. Ripoche, P. Dessen, M. Talbot, B. Caillou, J.-P. Levillain, M. Schlumberger, and J.-M. Bidart
Follicular Thyroid Tumors with the PAX8-PPAR{gamma}1 Rearrangement Display Characteristic Genetic Alterations
Am. J. Pathol., July 1, 2005; 167(1): 223 - 231.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
E. Frohlich, F. Machicao, and R. Wahl
Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture
Endocr. Relat. Cancer, June 1, 2005; 12(2): 291 - 303.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Lu, K. Imamura, S. Nomura, K.-i. Mafune, A. Nakajima, T. Kadowaki, N. Kubota, Y. Terauchi, G. Ishii, A. Ochiai, et al.
Chemopreventive Effect of Peroxisome Proliferator-Activated Receptor {gamma} on Gastric Carcinogenesis in Mice
Cancer Res., June 1, 2005; 65(11): 4769 - 4774.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Masuda, K. Wada, A. Nakajima, M. Okura, C. Kudo, T. Kadowaki, M. Kogo, and Y. Kamisaki
Critical Role of Peroxisome Proliferator-Activated Receptor {gamma} on Anoikis and Invasion of Squamous Cell Carcinoma
Clin. Cancer Res., June 1, 2005; 11(11): 4012 - 4021.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. P. Klopper, W. R. Hays, V. Sharma, M. A. Baumbusch, J. M. Hershman, and B. R. Haugen
Retinoid X receptor-{gamma} and peroxisome proliferator-activated receptor-{gamma} expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment
Mol. Cancer Ther., August 1, 2004; 3(8): 1011 - 1020.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
F. Bogazzi, F. Ultimieri, F. Raggi, D. Russo, R. Vanacore, C. Guida, S. Brogioni, C. Cosci, M. Gasperi, L. Bartalena, et al.
Growth Hormone Inhibits Apoptosis in Human Colonic Cancer Cell Lines: Antagonistic Effects of Peroxisome Proliferator Activated Receptor-{gamma} Ligands
Endocrinology, July 1, 2004; 145(7): 3353 - 3362.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
N. Strakova, J. Ehrmann, P. Dzubak, J. Bouchal, and Z. Kolar
The Synthetic Ligand of Peroxisome Proliferator-Activated Receptor-{gamma} Ciglitazone Affects Human Glioblastoma Cell Lines
J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 1239 - 1247.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
W K Leung, A H C Bai, V Y W Chan, J Yu, M W Y Chan, K-F To, J-R Wu, K-K Chan, Y-G Fu, F K L Chan, et al.
Effect of peroxisome proliferator activated receptor {gamma} ligands on growth and gene expression profiles of gastric cancer cells
Gut, March 1, 2004; 53(3): 331 - 338.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Kumagai, T. Ikezoe, D. Gui, J. O'Kelly, X.-J. Tong, F. J. Cohen, J. W. Said, and H. P. Koeffler
RWJ-241947 (MCC-555), A Unique Peroxisome Proliferator-Activated Receptor-{gamma} Ligand with Antitumor Activity against Human Prostate Cancer in Vitro and in Beige/Nude/ X-Linked Immunodeficient Mice and Enhancement of Apoptosis in Myeloma Cells Induced by Arsenic Trioxide
Clin. Cancer Res., February 15, 2004; 10(4): 1508 - 1520.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Ying, H. Suzuki, L. Zhao, M. C. Willingham, P. Meltzer, and S.-Y. Cheng
Mutant Thyroid Hormone Receptor {beta} Represses the Expression and Transcriptional Activity of Peroxisome Proliferator-activated Receptor {gamma} during Thyroid Carcinogenesis
Cancer Res., September 1, 2003; 63(17): 5274 - 5280.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
L. Pavan, A. Tarrade, A. Hermouet, C. Delouis, M. Titeux, M. Vidaud, P. Therond, D. Evain-Brion, and T. Fournier
Human invasive trophoblasts transformed with simian virus 40 provide a new tool to study the role of PPAR{gamma} in cell invasion process
Carcinogenesis, August 1, 2003; 24(8): 1325 - 1336.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
C. A. French, E. K. Alexander, E. S. Cibas, V. Nose, J. Laguette, W. Faquin, J. Garber, F. Moore Jr, J. A. Fletcher, P. R. Larsen, et al.
Genetic and Biological Subgroups of Low-Stage Follicular Thyroid Cancer
Am. J. Pathol., April 1, 2003; 162(4): 1053 - 1060.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. Cheung, M. Messina, A. Gill, A. Clarkson, D. Learoyd, L. Delbridge, J. Wentworth, J. Philips, R. Clifton-Bligh, and B. G. Robinson
Detection of the PAX8-PPAR{gamma} Fusion Oncogene in Both Follicular Thyroid Carcinomas and Adenomas
J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 354 - 357.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. C. Hsi, L. C. Wilson, and T. E. Eling
Opposing Effects of 15-Lipoxygenase-1 and -2 Metabolites on MAPK Signaling in Prostate. ALTERATION IN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR gamma
J. Biol. Chem., October 18, 2002; 277(43): 40549 - 40556.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. L. Martelli, R. Iuliano, I. Le Pera, I. Sama', C. Monaco, S. Cammarota, T. Kroll, L. Chiariotti, M. Santoro, and A. Fusco
Inhibitory Effects of Peroxisome Proliferator-Activated Receptor {gamma} on Thyroid Carcinoma Cell Growth
J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4728 - 4735.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
S. Muto, A. Aiba, Y. Saito, K. Nakao, K. Nakamura, K. Tomita, T. Kitamura, M. Kurabayashi, R. Nagai, E. Higashihara, et al.
Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant
Hum. Mol. Genet., July 15, 2002; 11(15): 1731 - 1742.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
Y. Terashita, H. Sasaki, N. Haruki, T. Nishiwaki, H. Ishiguro, Y. Shibata, J. Kudo, S. Konishi, J. Kato, H. Koyama, et al.
Decreased Peroxisome Proliferator-activated Receptor Gamma Gene Expression is Correlated with Poor Prognosis in Patients with Esophageal Cancer
Jpn. J. Clin. Oncol., July 1, 2002; 32(7): 238 - 243.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2001 by The Endocrine Society